[go: up one dir, main page]

WO2015195555A8 - Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk - Google Patents

Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk Download PDF

Info

Publication number
WO2015195555A8
WO2015195555A8 PCT/US2015/035831 US2015035831W WO2015195555A8 WO 2015195555 A8 WO2015195555 A8 WO 2015195555A8 US 2015035831 W US2015035831 W US 2015035831W WO 2015195555 A8 WO2015195555 A8 WO 2015195555A8
Authority
WO
WIPO (PCT)
Prior art keywords
cells
protein
antibody
protect
blocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/035831
Other languages
English (en)
Other versions
WO2015195555A1 (fr
Inventor
Richard W. Childs
Luis Espinoza CALDERON
Maria BERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2015195555A1 publication Critical patent/WO2015195555A1/fr
Publication of WO2015195555A8 publication Critical patent/WO2015195555A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés d'inhibition de la croissance ou la prolifération de cellules exprimant CD38 par la mise en contact des cellules exprimant CD38 avec 1) des cellules NK liées à un complexe anticorps anti-CD38-protéine G et 2) un anticorps anti-CD38, dans un ordre quelconque ou simultanément. L'invention concerne également des procédés de traitement ou d'inhibition d'un trouble hyperprolifératif ou d'un trouble auto-immun chez un sujet par l'administration au sujet 1) de cellules NK liées à un complexe anticorps anti-CD38-protéine G et 2) d'un anticorps anti-CD38, dans un ordre quelconque ou simultanément.
PCT/US2015/035831 2014-06-16 2015-06-15 Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk Ceased WO2015195555A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462012873P 2014-06-16 2014-06-16
US62/012,873 2014-06-16

Publications (2)

Publication Number Publication Date
WO2015195555A1 WO2015195555A1 (fr) 2015-12-23
WO2015195555A8 true WO2015195555A8 (fr) 2016-02-25

Family

ID=53443053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/035831 Ceased WO2015195555A1 (fr) 2014-06-16 2015-06-15 Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk

Country Status (1)

Country Link
WO (1) WO2015195555A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
EP3227338A4 (fr) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
JP2019527678A (ja) * 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
JP7239567B2 (ja) 2017-10-02 2023-03-14 ガミダ セル リミテッド Ｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
CA3079242A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methodes de traitement du myelome multiple a haut risque
CN109568585B (zh) * 2018-12-29 2021-04-23 常晓天 Cd38抑制剂在制备抗类风湿关节炎药物中的应用
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2555185C (fr) 2004-02-06 2020-03-24 Morphosys Ag Anticorps humains anti-cd38 et utilisations de ceux-ci
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
EA015584B1 (ru) * 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
US9844593B2 (en) * 2010-11-22 2017-12-19 Innate Pharma Sa Methods for treatment of recurrent hematological malignancies
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід

Also Published As

Publication number Publication date
WO2015195555A1 (fr) 2015-12-23

Similar Documents

Publication Publication Date Title
WO2015195555A8 (fr) Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk
WO2015195556A8 (fr) Blocage de cd38 à l'aide de f(ab')2 anti-cd38 pour protéger les cellules nk
PH12019500369A1 (en) Anti-tim-3 antibodies
PH12020500225A1 (en) Anti- cd137 antibodies
MY199019A (en) Pd-1 antibodies
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
WO2017031458A3 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
MY195110A (en) Antibodies to PD-1 and uses Thereof
EP4512829A3 (fr) Anticorps anti-tim3 et leurs utilisations
WO2016070089A3 (fr) Anticorps anti-cs1 et conjugués anticorps-médicament
HK1249023A1 (zh) Pd-l1("程序性死亡配体1")抗体
PH12017501748B1 (en) Antibodies to icos
PH12016501411B1 (en) Bifunctional cytotoxic agents
WO2014152969A3 (fr) Systèmes et procédés relatifs à un porte-clés sûr du type mousqueton
SG10201909716RA (en) Modified j-chain
IL260474B (en) Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment
WO2017015622A3 (fr) Protéines de liaison à gdf11 et leurs utilisations
WO2014144632A3 (fr) Anticorps anti-pac1 humains
WO2015200648A8 (fr) Utilisation de peptides qui bloquent l'interaction métadhérine-snd1 pour le traitement du cancer
EP3516195A4 (fr) Réduction de particules d'essence à l'aide d'un système optimisé d'injection de carburant dans un conduit d'admission et d'injection directe
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
SG10201803094QA (en) Monoliths with attached recognition compounds, arrays thereof and uses thereof
EP3286426B8 (fr) Système d'injection de carburant et amortisseur utilisé dans le système d'injection de carburant
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15730668

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15730668

Country of ref document: EP

Kind code of ref document: A1